The Sarcoma Assessment Measure (SAM) was developed as a sarcoma-specific patient-reported outcome measure to be used in clinical practice. We have reported in detail how SAM has been developed in collaboration with patients and healthcare professionals. The aim of this paper is to report the preliminary validation of SAM. The 22-item SAM was administered alongside a validated quality of life questionnaire and measure of activities of daily living. Linear modelling was used to build a measure, which had predictive validity in comparison to more established outcome measures. Of the 762 patients who participated in the study, 44.1% identified as male, and participant age ranged from 13 to 82 years. Clinically, participants presented with a range of soft tissue (82.2%) and bone (21.8%) sarcomas. Our preliminary analysis indicates that SAM accounts for 35% of the global quality of life scale and 18% of the Toronto Extremity Salvage Scale (TESS); so psychometrically, it overlaps with quality of life and activities of daily living, but also measures distinct concerns. This demonstrates that this measure picks up issues that are important to patients with sarcoma that are not reflected in other measures. We have established the preliminary validity of SAM and believe it has utility as a patient-reported outcome measure both as a research tool and for assessing the impact of symptoms and dysfunction related to sarcoma as part of clinical care. Further validation using a larger and more clinically diverse sample is now needed.
肉瘤评估量表（SAM）是专为临床实践设计的肉瘤特异性患者报告结局指标。我们已详细报告了如何与患者及医疗专业人员协作开发该量表。本文旨在报告SAM的初步验证结果。研究采用包含22个条目的SAM量表，同时辅以经过验证的生活质量问卷及日常生活活动能力评估工具。通过线性建模构建的测量工具，在与更成熟的结局指标比较中显示出预测效度。参与研究的762名患者中，44.1%为男性，年龄范围13至82岁。临床表现为软组织肉瘤（82.2%）和骨肉瘤（21.8%）等多种类型。初步分析表明，SAM可解释整体生活质量量表35%的变异度和多伦多肢体挽救评分（TESS）18%的变异度；心理测量学显示其与生活质量及日常生活活动能力既存在重叠，又能测量独特关注点。这证明该量表能捕捉对肉瘤患者重要但未被其他量表反映的问题。我们已确立SAM的初步效度，认为其作为患者报告结局指标，既可成为研究工具，也能作为临床护理中评估肉瘤相关症状及功能障碍影响的有效手段。目前需要通过更大规模、更具临床多样性的样本进行进一步验证。
肿瘤(癌症)患者之家